NASDAQ · DRMA
Dermata Therapeutics, Inc.
$0.84-$0.03 (-3.84%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.95% below the high.
Loading market information…
NASDAQ · ELAB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PMGC Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PMGC Holdings Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.84-$0.03 (-3.84%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.95% below the high.
$1.03-$0.02 (-1.9%)
XORTX Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.39% below the high.
$1.32+$0.12 (+10.0%)
Virax Biolabs Group Limited’s quoted price sits in the lower half of its reported 52-week range, 93.93% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
$0.38$0.00 (0.0%)
Avenue Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.8% below the high.
$2.69-$0.01 (-0.3%)
NewcelX Ltd.’s quoted price sits in the lower half of its reported 52-week range, 67.57% below the high.
$1.37-$0.14 (-9.27%)
Moolec Science S.A.’s quoted price sits in the lower half of its reported 52-week range, 94.1% below the high.
$0.15+$0.02 (+11.11%)
BriaCell Therapeutics Corp. Warrant’s quoted price sits in the lower half of its reported 52-week range, 65.91% below the high.
